Research programme: monoclonal antibody therapeutics - Gmax Biopharm

Drug Profile

Research programme: monoclonal antibody therapeutics - Gmax Biopharm

Alternative Names: GMA 103; GMA 104; GMA 202

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gmax Biopharm
  • Class Analgesics; Antihyperglycaemics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus
  • Research Cancer

Most Recent Events

  • 01 Nov 2017 Research programme: monoclonal antibody therapeutics - Gmax Biopharm is available for licensing in World as of 01 Nov 2017. http://www.gmaxbiopharm.com/job.html
  • 01 Nov 2017 Preclinical trials of GMA 103 in Type-2 diabetes mellitus in China (Parenteral) (Gmax Biopharm pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top